This database contains 50 studies, archived under the term: "phenylcarbamates"
Click here to filter this large number of results.
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study
Santoro, Aurelia,
Siviero, Paola,
Minicuci, Nadia,
Bellavista, Elena,
Mishto, Michele,
Olivieri, Fabiola,
Marchegiani, Francesca,
Chiamenti, Andrea Maria,
Benussi, Luisa,
Ghidoni, Roberta,
Nacmias, Benedetta,
Bagnoli, Silvia,
Ginestroni, Andrea,
Scarpino, Osvaldo,
Feraco, Emidio,
Gianni, Walter,
Cruciani, Guido,
Paganelli, Roberto,
Di Iorio, Angelo,
Scognamiglio, Mario,
Grimaldi, Luigi Maria Edoardo,
Gabelli, Carlo,
Sorbi, Sandro,
Binetti, Giuliano,
Crepaldi, Gaetano,
Franceschi, Claudio
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer’s disease: a 26-week, open-label, prospective trial (Study ENA713B US32)
Olin, Jason T.,
Bhatnagar, Vinod,
Reyes, Patricio,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]
Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer’s disease: a prospective post-marketing surveillance study
Chiu, Pai-Yi,
Dai, Dao-En,
Hsu, Hai-Pei,
Lee, Chao,
Lin, Juei-Jueng,
Kuo, Hung-Chou,
Huang, Ying-Chih,
Liu, Yung-Chang,
Tsai, Ching-Piao
Background and Objectives: Rivastigmine is approved for the symptomatic treatment of mild to moderate dementia in patients with Alzheimer’s disease. The drug was launched in Taiwan in 2000. The primary objective of this post-marketing surveillance (PMS) study was to describe the safety/tolerability of treatment with rivastigmine capsules in patients with Alzheimer’s disease. The secondary objectives […]
Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study
Taipale, Heidi,
Tanskanen, Antti,
Koponen, Marjaana,
Tolppanen, Anna-Maija,
Tiihonen, Jari,
Hartikainen, Sirpa
The objective of this study was to investigate the prevalence of acetylcholinesterase inhibitor (AChEI) and memantine use, duration of treatment, concomitant use of these drugs, and factors associated with the discontinuation of AChEI therapy during 2006-2009. We utilized data from a nationwide sample of community-dwelling individuals with a clinically verified Alzheimer’s disease diagnosed during the […]
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study
Simioni, S.,
Cavassini, M.,
Annoni, J.-M.,
Metral, M.,
Iglesias, K.,
Rimbault Abraham, A.,
Jilek, S.,
Calmy, A.,
Muller, H.,
Fayet-Mello, A.,
Giacobini, E.,
Hirschel, B.,
Du Pasquier, R. A.
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]
Cognitive function in early clinical phase huntington disease after rivastigmine treatment
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]